Loading
Candel Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 26 Feb 2026.
Candel Therapeutics, Inc.: what insiders have been doing
Headquartered in Auburndale, United States, Candel Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 11 filings came from 8 insiders.
Open-market activity splits into 1 purchase totalling €2.5M and 5 sales totalling €2.8M; 1 insider sit on the buying side and 3 insiders on the selling side. The totals do not cover 2 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 1 senior executive. The largest single trade was a purchase of €2.5M by Manning Paul B, published on 26 February 2026.
The clock since the last published purchase (26 February 2026) now reads 234 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
With 11 filings in twelve months, the company is quieter than the median of 22 filings across the 5,458 companies we follow on the same exchange. The full history, which starts in 2021, counts 13 purchases against 36 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
102
Thresholds
n/a
Buy Volume
€6M
13 ops. · all time
Sell Volume
€6M
36 ops. · all time
Who traded when
BuySalePaul Peter Tak6 sales
Seshu Tyagarajan6 sales
Francesca Barone4 sales
Charles Schoch3 sales
William Garrett Nichols3 sales
Paul B. Manning2 buys
Since the insiders bought
- +54.1%Entry US$5.25 · Close at T+90 US$8.09
- -55.7%Entry US$7.50 · Close at T+365 US$3.32
- -55.7%Entry US$7.50 · Close at T+365 US$3.32
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.19
Analyst consensus
8 analysts1.00/5
US$15.00Target US$21.75(+166%)US$29.00
Income statement
EBITDA-US$35.2M
Net income-US$38.2M0.0% margin
Valuation
PER (forward)-13.1x
P/Book4.9x
Beta-0.31
Balance sheet & cash
Market capUS$626.7M
Total debtUS$49M
Free Cash Flow-US$38.9M
Debt / Equity39%
Profitability & ownership
ROE-81.8%
ROA-28.6%
% insiders14.6%
% institutions67.7%
Last declaration on 11 September 2026
Declarations102 total
220,866 shares@ US$11.49970.29% mcap51.2% of flowCommon StockSEC:0001873905-26-000002:1
59,379 shares@ US$10.45640.072% mcap12.5% of flowCommon StockSEC:0001873905-26-000002:2
125,000 shares@ US$1.550.022% mcap3.9% of flowCommon StockSEC:0001873905-26-000002:0
280,245 shares@ US$12.170.40% mcap100.0% of flowCommonSEC144:0001950047-26-009295
7,000 shares@ US$12.000.0098% mcap8.5% of flowCommon StockSEC:0001923794-26-000004:0
7,000 shares@ US$11.720.0096% mcap100.0% of flowCommonSEC144:0001950047-26-008263
23,447 sharesCommon StockSEC:0001909680-26-000002:0
7,000 sharesCommon StockSEC:0001923794-26-000002:0
7,000 shares@ US$9.790.0081% mcap100.0% of flowCommonSEC144:0001950047-26-006607
23,447 shares@ US$9.790.027% mcap100.0% of flowCommonSEC144:0001950047-26-006597
550,458 shares@ US$5.4525.6% of flowCommon StockSEC:0001193125-26-078246:0
Canonical exit: 24 May 2026 (T+90)
937 shares@ US$1.290.3% of flowCommon StockSEC:0000950170-25-100320:0
781 shares@ US$1.290.2% of flowCommon StockSEC:0000950170-25-093035:0
5,353 shares@ US$4.672.5% of flowCommon StockSEC:0000950170-25-090199:0
42,826 shares@ US$4.674.0% of flowCommon StockSEC:0000950170-25-090198:0
1,070,663 shares@ US$4.6743.3% of flowCommon StockSEC:0000950170-25-090197:0
111,349 shares@ US$4.6798.9% of flowCommon StockSEC:0000950170-25-090196:0
2,141 shares@ US$4.67100.0% of flowCommon StockSEC:0000950170-25-090195:0
4,282 shares@ US$4.673.3% of flowCommon StockSEC:0000950170-25-090194:0
5,353 shares@ US$4.676.8% of flowCommon StockSEC:0000950170-25-090193:0
5,353 shares@ US$4.67100.0% of flowCommon StockSEC:0000950170-25-090192:0
64,239 shares@ US$4.6798.1% of flowCommon StockSEC:0000950170-25-090191:0
4,584 shares@ US$3.754.3% of flowCommon StockSEC:0000950170-25-042728:0
20,000 shares@ US$1.292.8% of flowCommon StockSEC:0000950170-25-042724:0
25,772 shares@ US$8.77014.9% of flowCommon StockSEC:0000950170-25-042725:0
25 of 102 declarations
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc. (ticker: CADL) is a clinical-stage biopharmaceutical company listed on the NASDAQ market in the United States. Headquartered in Needham, Massachusetts, the company develops multimodal biological immunotherapies designed to improve outcomes for cancer patients. Its business model is centered on research and development rather than commercialization, and it currently has no marketed products. As a result, Candel fits the profile of a high-risk, high-upside oncology biotech whose valuation is driven primarily by clinical data, regulatory milestones, and financing execution.
Founded in June 2003 under the laws of Delaware, Candel has evolved into a platform company focused on viral and biological immunotherapy. Its scientific approach is built around oncolytic viral technologies intended to trigger in situ immunization against tumor-specific antigens and neoantigens after tumor cell lysis. The company’s two principal clinical candidates are CAN-2409, also known as aglatimagene besadenovec, and CAN-3110, also known as linoserpaturev. CAN-2409 is Candel’s most advanced asset and is being evaluated in localized prostate cancer, non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC). CAN-3110 is being developed primarily for recurrent glioblastoma, extending the platform into a particularly challenging solid-tumor setting.
Read moreShow less
From a competitive standpoint, Candel operates in a specialized segment of oncology that sits between oncolytic virotherapy, gene therapy, and precision immuno-oncology. Its differentiation lies in a proprietary platform and a relatively broad clinical pipeline for a company of its size. However, it competes with larger biotechnology and pharmaceutical companies that have deeper resources, broader commercial infrastructure, and stronger balance sheets. For investors, this means the investment case remains highly binary: success will depend on clinical efficacy, tolerability, and eventual regulatory success.
Recent corporate developments have been material. In 2026, Candel reported continued progress across its pipeline, including encouraging interim data for CAN-3110 in recurrent glioblastoma. The company also said it raised approximately $100 million in an equity offering in February 2026 and later entered into a $100 million royalty funding agreement with RTW to help support a potential launch of aglatimagene besadenovec in localized prostate cancer. Management has also stated that successful phase 2a studies were completed in NSCLC and PDAC, while corporate priorities have shifted toward prostate cancer and NSCLC development. For investors following the NYSE/NASDAQ U.S. healthcare universe, CADL remains a development-stage oncology story with meaningful event-driven catalysts and significant execution risk.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
